We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

57 hedge funds and large institutions have $13.6M invested in Matinas BioPharma in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

22% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 9

4% more funds holding

Funds holding: 55 → 57 (+2)

0.01% less ownership

Funds ownership: 0.26% → 0.25% (-0.01%)

24% less capital invested

Capital invested by funds: $18M → $13.6M (-$4.38M)

Holders
57
Holders Change
+2
Holders Change %
+3.64%
% of All Funds
0.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
11
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$159K
2
SIG
Sargent Investment Group
Maryland
+$118K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$117K
4
GRP
Global Retirement Partners
California
+$92.5K
5
VF
Virtu Financial
New York
+$78.4K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.04M
2
BCM
Bridgeway Capital Management
Texas
-$66.5K
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$63K
4
MA
MONECO Advisors
Connecticut
-$19K
5
GAA
Global Assets Advisory
Florida
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$4.3M +$117K +3,527 +2%
SIG
2
Sargent Investment Group
Maryland
$2.19M +$118K +3,554 +4%
BlackRock
3
BlackRock
New York
$1.36M -$1.04M -31,259 -37%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$902K +$76.3K +2,293 +7%
NRS
5
Neville Rodie & Shaw
New York
$877K – – –
AWA
6
Arkadios Wealth Advisors
Georgia
$700K – – –
JEST
7
JTC Employer Solutions Trustee
Jersey
$384K – – –
State Street
8
State Street
Massachusetts
$356K – – –
BCM
9
Bridgeway Capital Management
Texas
$327K -$66.5K -2,000 -13%
LPL Financial
10
LPL Financial
California
$317K +$9.98K +300 +2%
SCA
11
STALEY CAPITAL ADVISERS
Pennsylvania
$300K – – –
MSFS
12
Main Street Financial Solutions
Pennsylvania
$200K – – –
Northern Trust
13
Northern Trust
Illinois
$173K – – –
CCM
14
Courage Capital Management
Tennessee
$166K – – –
Millennium Management
15
Millennium Management
New York
$120K +$159K +4,788 New
Jane Street
16
Jane Street
New York
$103K +$47.6K +1,430 +54%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$82.8K -$399 -12 -0.4%
PTP
18
Platform Technology Partners
New York
$81.2K – – –
VF
19
Virtu Financial
New York
$72K +$78.4K +2,357 +449%
GRP
20
Global Retirement Partners
California
$69.5K +$92.5K +2,780 New
Renaissance Technologies
21
Renaissance Technologies
New York
$61K +$58.1K +1,746 +258%
CDH
22
Charles D. Hyman
$40K – – –
Charles Schwab
23
Charles Schwab
California
$39.2K – – –
BFG
24
Bleakley Financial Group
New Jersey
$30K +$39.9K +1,200 New
HF
25
HRT Financial
New York
$27K +$27.6K +831 +320%
1
2 3

MTNB Hedge Fund Activity: Q4 2022 in Review

57 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2022, worth a combined $13.6M — down 24% from $18M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new MTNB positions and 6 closed out — a net gain of 3 holders — while 11 added to existing stakes and 9 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $159K. The largest seller was BlackRock, cutting an estimated $1.04M.

  • 57 institutional investors held Matinas BioPharma (MTNB) as of Q4 2022, up from 55 in Q3 2022.
  • Funds reported $13.6M of Matinas BioPharma stock for Q4 2022, down 24% quarter-over-quarter.
  • 9 funds opened new Matinas BioPharma positions in Q4 2022 and 6 closed out, a net change of +3 holders.
  • The largest Matinas BioPharma buyer in Q4 2022 was Millennium Management, an estimated $159K added.
  • The largest Matinas BioPharma seller in Q4 2022 was BlackRock, an estimated $1.04M sold.

Based on aggregated 13F filings for Q4 2022.